Contact Us
Drug Search Results
More Filters [+]

Doxepin

Alternative Names: doxepin, mf 10, zonalon, silenor, sinequan, prudoxin
Latest Update: 2024-09-24
Latest Update Note: News Article

Product Description

Doxepin is used to treat anxiety or depression. It is also used to treat insomnia (trouble with sleeping). Doxepin is a tricyclic antidepressant (TCA). It works on the central nervous system (CNS) to increase levels of certain chemicals in the brain. This medicine is available only with your doctor's prescription.

Mechanisms of Action: SNR Inhibitor,H1 Antagonist,MR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Bangladesh | Canada | Chile | Egypt | France | Germany | Greece | Hong Kong | India | Indonesia | Ireland | Israel | Italy | Korea | Lebanon | New Zealand | Norway | Pakistan | Poland | Portugal | Romania | Slovenia | South Africa | Spain | Sri Lanka | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States

Approved Indications: Insomnia

Known Adverse Events: Respiratory Tract Infections

Company: Currax Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Doxepin

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Insomnia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20220868

P2

Completed

Insomnia

2022-10-25

Recent News Events

Date

Type

Title

09/24/2024

News Article

 Currax Pharmaceuticals Unveils New Disease Awareness Campaign to "Quiet the Food Noise," a Key Barrier for Individuals Seeking Weight Loss

09/27/2023

News Article

 Sleeping Pills Market Application, Development, Segment 2030

09/03/2023

News Article

 This report provides a detailed analysis of the Sleeping Pills market, with a focus on new trend analysis and competition tracking, while forecasting a CAGR of 12.6% from 2023 to 2030.

07/28/2023

News Article

 Generic Drugs Market Revenue to Hit USD 7,38,530 Million By 2032

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions